Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
Iveric Bio’s Izervay for Geographic Atrophy Approved by FDA
Parent company Astellas Pharma announced that Iveric Bio has received FDA approval for Izervay (avacincaptad pegol intravitreal solution) to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD). As a new complement C5 inhibitor, Izervay stands out as the sole…
Best Treatment for Uveitic Macular Edema Identified
Repeat corticosteroid injections were found to be more effective in improving vision for individuals with persistent or recurrent uveitis-related macular edema compared to methotrexate or ranibizumab intravitreal injections, according to a recent clinical trial. The corticosteroid treatment exhibited superior results…
Naegis Pharma Funds Novel Eye Drug
Naegis Pharmaceuticals Inc., a life sciences company specializing in inflammation and ophthalmology, announced the successful closure of a financing round to advance its lead compound, N0651, towards a Phase 2 clinical trial. This funding will support the compound’s progression through…
Glaucomatous Optic Neuropathy & Latest Treatments
Glaucomatous optic neuropathy is characterized by progressive loss of retinal ganglion cells (RGCs) and their axons and leads to measureable structural and functional damage to the optic nerve, visual impairment, and blindness. The primary site of injury is thought to be…
SpyGlass Pharma Secures $90M in Funding
SpyGlass Pharma has successfully closed a Series C financing round, raising $90 million. RA Capital Management led the funding round, joined by existing investors New Enterprise Associates (NEA) and Vensana Capital, as well as new investors Samsara BioCapital and Vertex…
Ocugen Completes Dosing in Key Trial for GA Treatment
Ocugen has officially completed dosing in the second cohort of its phase 1/2 ArMaDa trial of OCU410, a novel gene therapy designed to treat geographic atrophy (GA). The therapy, known as adeno-associated viral vector 5 human RORA (AAV5-hRORA), is being…
A novel multi-ingredient supplement significantly improves ocular symptom severity and tear production in patients with dry eye disease: results from a randomized, placebo-controlled clinical trial – Frontiers
A novel multi-ingredient supplement significantly improves ocular symptom severity and tear production in patients with dry eye disease: results from a randomized, placebo-controlled clinical trial Frontiers Source: Author: | Date: 2024-04-23 07:00:00 Source: Author: | Date: 2024-04-23 07:00:00
Ocular Therapeutix Reports Promising Axpaxli Results in DR Study
Ocular Therapeutix announced positive topline results from its phase 1 HELIOS study, which evaluated the safety, tolerability, and efficacy of Axpaxli versus a sham control in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR) without diabetic macular edema…
Kiora Receives Key Grant for Clinical Trials in Vision Impairment
Kiora Pharmaceuticals announced that it has secured a grant from the Choroideremia Research Foundation (CRF) to support novel clinical trial endpoints for inherited retinal diseases (IRDs). The grant will fund the validation of the Multiluminence Orientation & Mobility (MLOM™) suite…
Lenz Therapeutics Reports Study Success for Presbyopia
Lenz Therapeutics announced positive topline results from its Phase 3 CLARITY study, evaluating two investigational formulations, LNZ100 and LNZ101, aimed at treating presbyopia. The study’s findings showcase the effectiveness and safety of these formulations, particularly highlighting LNZ100 (1.75% aceclidine) for…